// <auto-generated/>
// Contents of: hl7.fhir.r4.core version: 4.0.1
// Minimum TypeScript Version: 3.7
// FHIR ValueSet: http://hl7.org/fhir/ValueSet/research-study-phase|4.0.1
/**
 * Codes for the stage in the progression of a therapy from initial experimental use in humans in clinical trials to post-market evaluation.
 */
export const ResearchStudyPhaseCodings = {
    /**
     * early-phase-1: Designation for optional exploratory trials conducted in accordance with the United States Food and Drug Administration's (FDA) 2006 Guidance on Exploratory Investigational New Drug (IND) Studies. Formerly called Phase 0.
     */
    EarlyPhase1: {
        display: "Early Phase 1",
        code: "early-phase-1",
        system: "http://terminology.hl7.org/CodeSystem/research-study-phase",
    },
    /**
     * n-a: Trials without phases (for example, studies of devices or behavioral interventions).
     */
    NA: {
        display: "N/A",
        code: "n-a",
        system: "http://terminology.hl7.org/CodeSystem/research-study-phase",
    },
    /**
     * phase-1: Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
     */
    Phase1: {
        display: "Phase 1",
        code: "phase-1",
        system: "http://terminology.hl7.org/CodeSystem/research-study-phase",
    },
    /**
     * phase-1-phase-2: Trials that are a combination of phases 1 and 2.
     */
    Phase1Phase2: {
        display: "Phase 1/Phase 2",
        code: "phase-1-phase-2",
        system: "http://terminology.hl7.org/CodeSystem/research-study-phase",
    },
    /**
     * phase-2: Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
     */
    Phase2: {
        display: "Phase 2",
        code: "phase-2",
        system: "http://terminology.hl7.org/CodeSystem/research-study-phase",
    },
    /**
     * phase-2-phase-3: Trials that are a combination of phases 2 and 3.
     */
    Phase2Phase3: {
        display: "Phase 2/Phase 3",
        code: "phase-2-phase-3",
        system: "http://terminology.hl7.org/CodeSystem/research-study-phase",
    },
    /**
     * phase-3: Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
     */
    Phase3: {
        display: "Phase 3",
        code: "phase-3",
        system: "http://terminology.hl7.org/CodeSystem/research-study-phase",
    },
    /**
     * phase-4: Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
     */
    Phase4: {
        display: "Phase 4",
        code: "phase-4",
        system: "http://terminology.hl7.org/CodeSystem/research-study-phase",
    },
};
//# sourceMappingURL=data:application/json;base64,{"version":3,"file":"ResearchStudyPhaseCodings.js","sourceRoot":"./src/","sources":["fhirValueSets/ResearchStudyPhaseCodings.ts"],"names":[],"mappings":"AAAA,oBAAoB;AACpB,+CAA+C;AAC/C,kCAAkC;AAClC,yEAAyE;AA0CzE;;GAEG;AACH,MAAM,CAAC,MAAM,yBAAyB,GAAgC;IACpE;;OAEG;IACH,WAAW,EAAE;QACX,OAAO,EAAE,eAAe;QACxB,IAAI,EAAE,eAAe;QACrB,MAAM,EAAE,4DAA4D;KACrE;IACD;;OAEG;IACH,EAAE,EAAE;QACF,OAAO,EAAE,KAAK;QACd,IAAI,EAAE,KAAK;QACX,MAAM,EAAE,4DAA4D;KACrE;IACD;;OAEG;IACH,MAAM,EAAE;QACN,OAAO,EAAE,SAAS;QAClB,IAAI,EAAE,SAAS;QACf,MAAM,EAAE,4DAA4D;KACrE;IACD;;OAEG;IACH,YAAY,EAAE;QACZ,OAAO,EAAE,iBAAiB;QAC1B,IAAI,EAAE,iBAAiB;QACvB,MAAM,EAAE,4DAA4D;KACrE;IACD;;OAEG;IACH,MAAM,EAAE;QACN,OAAO,EAAE,SAAS;QAClB,IAAI,EAAE,SAAS;QACf,MAAM,EAAE,4DAA4D;KACrE;IACD;;OAEG;IACH,YAAY,EAAE;QACZ,OAAO,EAAE,iBAAiB;QAC1B,IAAI,EAAE,iBAAiB;QACvB,MAAM,EAAE,4DAA4D;KACrE;IACD;;OAEG;IACH,MAAM,EAAE;QACN,OAAO,EAAE,SAAS;QAClB,IAAI,EAAE,SAAS;QACf,MAAM,EAAE,4DAA4D;KACrE;IACD;;OAEG;IACH,MAAM,EAAE;QACN,OAAO,EAAE,SAAS;QAClB,IAAI,EAAE,SAAS;QACf,MAAM,EAAE,4DAA4D;KACrE;CACO,CAAC","sourcesContent":["// <auto-generated/>\r\n// Contents of: hl7.fhir.r4.core version: 4.0.1\r\n// Minimum TypeScript Version: 3.7\r\n// FHIR ValueSet: http://hl7.org/fhir/ValueSet/research-study-phase|4.0.1\r\n\r\nimport { CodingArgs } from '../fhir/Coding.js'\r\n\r\n/**\r\n * Codes for the stage in the progression of a therapy from initial experimental use in humans in clinical trials to post-market evaluation.\r\n */\r\nexport type ResearchStudyPhaseCodingType = {\r\n  /**\r\n   * early-phase-1: Designation for optional exploratory trials conducted in accordance with the United States Food and Drug Administration's (FDA) 2006 Guidance on Exploratory Investigational New Drug (IND) Studies. Formerly called Phase 0.\r\n   */\r\n  EarlyPhase1: CodingArgs;\r\n  /**\r\n   * n-a: Trials without phases (for example, studies of devices or behavioral interventions).\r\n   */\r\n  NA: CodingArgs;\r\n  /**\r\n   * phase-1: Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.\r\n   */\r\n  Phase1: CodingArgs;\r\n  /**\r\n   * phase-1-phase-2: Trials that are a combination of phases 1 and 2.\r\n   */\r\n  Phase1Phase2: CodingArgs;\r\n  /**\r\n   * phase-2: Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.\r\n   */\r\n  Phase2: CodingArgs;\r\n  /**\r\n   * phase-2-phase-3: Trials that are a combination of phases 2 and 3.\r\n   */\r\n  Phase2Phase3: CodingArgs;\r\n  /**\r\n   * phase-3: Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.\r\n   */\r\n  Phase3: CodingArgs;\r\n  /**\r\n   * phase-4: Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.\r\n   */\r\n  Phase4: CodingArgs;\r\n}\r\n\r\n/**\r\n * Codes for the stage in the progression of a therapy from initial experimental use in humans in clinical trials to post-market evaluation.\r\n */\r\nexport const ResearchStudyPhaseCodings:ResearchStudyPhaseCodingType = {\r\n  /**\r\n   * early-phase-1: Designation for optional exploratory trials conducted in accordance with the United States Food and Drug Administration's (FDA) 2006 Guidance on Exploratory Investigational New Drug (IND) Studies. Formerly called Phase 0.\r\n   */\r\n  EarlyPhase1: {\r\n    display: \"Early Phase 1\",\r\n    code: \"early-phase-1\",\r\n    system: \"http://terminology.hl7.org/CodeSystem/research-study-phase\",\r\n  },\r\n  /**\r\n   * n-a: Trials without phases (for example, studies of devices or behavioral interventions).\r\n   */\r\n  NA: {\r\n    display: \"N/A\",\r\n    code: \"n-a\",\r\n    system: \"http://terminology.hl7.org/CodeSystem/research-study-phase\",\r\n  },\r\n  /**\r\n   * phase-1: Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.\r\n   */\r\n  Phase1: {\r\n    display: \"Phase 1\",\r\n    code: \"phase-1\",\r\n    system: \"http://terminology.hl7.org/CodeSystem/research-study-phase\",\r\n  },\r\n  /**\r\n   * phase-1-phase-2: Trials that are a combination of phases 1 and 2.\r\n   */\r\n  Phase1Phase2: {\r\n    display: \"Phase 1/Phase 2\",\r\n    code: \"phase-1-phase-2\",\r\n    system: \"http://terminology.hl7.org/CodeSystem/research-study-phase\",\r\n  },\r\n  /**\r\n   * phase-2: Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.\r\n   */\r\n  Phase2: {\r\n    display: \"Phase 2\",\r\n    code: \"phase-2\",\r\n    system: \"http://terminology.hl7.org/CodeSystem/research-study-phase\",\r\n  },\r\n  /**\r\n   * phase-2-phase-3: Trials that are a combination of phases 2 and 3.\r\n   */\r\n  Phase2Phase3: {\r\n    display: \"Phase 2/Phase 3\",\r\n    code: \"phase-2-phase-3\",\r\n    system: \"http://terminology.hl7.org/CodeSystem/research-study-phase\",\r\n  },\r\n  /**\r\n   * phase-3: Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.\r\n   */\r\n  Phase3: {\r\n    display: \"Phase 3\",\r\n    code: \"phase-3\",\r\n    system: \"http://terminology.hl7.org/CodeSystem/research-study-phase\",\r\n  },\r\n  /**\r\n   * phase-4: Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.\r\n   */\r\n  Phase4: {\r\n    display: \"Phase 4\",\r\n    code: \"phase-4\",\r\n    system: \"http://terminology.hl7.org/CodeSystem/research-study-phase\",\r\n  },\r\n} as const;\r\n"]}